US 12168054
Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
granted A61KA61K2039/505A61K2039/545
Quick answer
US patent 12168054 (Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody) held by Syndax Pharmaceuticals, Inc. expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Syndax Pharmaceuticals, Inc.
- Grant date
- Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K31/4406, A61K39/39541